PTGX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 2.12%, SMA50 -1.66%, SMA200 27.53%). The stock’s 14-day RSI is 52.04 (neutral), while the ATR of 3.59 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.48% below its high and over 150.71% above its low. Average 10-day trading volume of 835.15 thousand shares is in line with the 3-month average of 836.08 thousand, indicating normal recent market interest.

The latest quarter delivered EPS of -$0.62. The next quarter is forecast at -$0.33. Next year's EPS is expected at -$42.69. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 17 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $118.00 to $54.00. The high target offers 41.62% upside. The low target suggests -35.19% downside. The mean target is $82.52. This offers -0.96% upside. Protagonist Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 5.08%. The prior quarter beat by 3.77%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 06, 2024.

Protagonist Therapeutics, Inc. has 62.21 million shares outstanding. The public float is 43.15 million shares, elevated short interest at 11.10% of float. This equals 5.76 million shares. The short ratio is 7.93 days. Institutional investors hold 117.44% of the float. Insiders own 1.02%. Papanek Julie holds 2.45 million shares, JOHNSON & JOHNSON has 2.45 million shares and CANAAN X L.P. has 2.12 million shares. Over the past six months, insider transactions show net selling. They sold 170.19 thousand shares across 15 transactions.

Protagonist Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.33. This means the shares are trading above this model’s fair value.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) closed at $83.32 USD, losing -$1.17 (-1.38%) from the previous close of $84.49. The stock is currently mid-range between its 52-week high and low $33.70 and $96.54. With a market capitalization of about $5.21 billion, Protagonist Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.25). Key stats such as the average daily volume over the past year has been around 904.37 thousand shares, volume is running light vs its 52-week average. Headquartered in Newark, CA, Protagonist Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dinesh V. Patel, the company employs approximately 124 people and listed since August 11, 2016. Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.

Protagonist Therapeutics, Inc. trades at a P/E ratio of 114.78, slightly above the S&P 500 average, with a price-to-sales ratio of 24.69 and a price-to-book ratio of 8.16 trading at moderately above to book value. The P/FCF stands at 81.08, also above market averages.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) shares are flat -4.49% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Protagonist Therapeutics, Inc. trading at a premium to the broader market with a P/E of 114.78. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $58.93, suggesting -29.27% downside. Our AI forecast model points to short-term weakness (-0.55% over two weeks), a medium-term rise (14.83% over three months), and a longer-term gain (25.19% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Protagonist Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.55%, with price expected at $82.86 by February 20, 2026, within a range of $80.77 to $85.07 3-Month Outlook: Projected rise of 14.83%, reaching $95.68 by May 07, 2026, with a range of $94.26 to $97.20. 1-Year Outlook: Projected gain of 25.19%, with price at $104.31 by February 05, 2027, within a range of $101.33 to $108.08.